Nektar Therapeutics Interest Expense
Nektar Therapeutics (NKTR) reported Interest Expense of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-28.
Discontinued › Expense Statement › Interest Expense
us-gaap:InterestExpense · last filed 2023-02-28
- Nektar Therapeutics interest expense for the quarter ending 2021-12-31 was $0.00.
- Nektar Therapeutics interest expense for the quarter ending 2021-09-30 was $0.00.
- Nektar Therapeutics interest expense for the quarter ending 2021-06-30 was $0.00, a 100.00% decline year-over-year.
- Nektar Therapeutics interest expense for the quarter ending 2021-03-31 was $0.00, a 100.00% decline year-over-year.
- Nektar Therapeutics interest expense for fiscal 2022 was $0.00.
- Nektar Therapeutics interest expense for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- Nektar Therapeutics interest expense for fiscal 2020 was $6.85M, a 67.85% decline from fiscal 2019.
- Nektar Therapeutics interest expense for fiscal 2019 was $21.31M, a 1.26% decline from fiscal 2018.
| Period end | Interest Expense 3 month | Interest Expense 3 month as first filed | Interest Expense 6 month | Interest Expense 6 month as first filed | Interest Expense 9 month | Interest Expense 9 month as first filed | Interest Expense 12 month |
|---|---|---|---|---|---|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-02-28 | ||||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $0.00 derived: sum of 2 quarters · filed 2023-02-28 | $0.00 derived: sum of 3 quarters · filed 2023-02-28 | $0.00 10-K · filed 2023-02-28 | |||
| 2021-09-30 | $0.00 10-Q · filed 2021-11-05 | $0.00 derived: sum of 2 quarters · filed 2021-11-05 | $0.00 10-Q · filed 2021-11-05 | $0.00 derived: sum of 4 quarters · filed 2023-02-28 | |||
| 2021-06-30 | $0.00 10-Q · filed 2021-08-06 | $0.00 10-Q · filed 2021-08-06 | $0.00 derived: sum of 3 quarters · filed 2023-02-28 | $0.00 derived: sum of 4 quarters · filed 2023-02-28 | |||
| 2021-03-31 | $0.00 10-Q · filed 2021-05-07 | $0.00 derived: sum of 2 quarters · filed 2023-02-28 | $0.00 derived: sum of 3 quarters · filed 2023-02-28 | $647.00K derived: sum of 4 quarters · filed 2023-02-28 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $0.00 derived: sum of 2 quarters · filed 2023-02-28 | $647.00K derived: sum of 3 quarters · filed 2023-02-28 | $6.85M 10-K · filed 2023-02-28 | |||
| 2020-09-30 | $0.00 10-Q · filed 2021-11-05 | $647.00K derived: sum of 2 quarters · filed 2021-11-05 | $6.85M 10-Q · filed 2021-11-05 | $12.28M derived: sum of 4 quarters · filed 2022-03-01 | |||
| 2020-06-30 | $647.00K 10-Q · filed 2021-08-06 | $6.85M 10-Q · filed 2021-08-06 | $12.28M derived: sum of 3 quarters · filed 2022-03-01 | $17.70M derived: sum of 4 quarters · filed 2022-03-01 | |||
| 2020-03-31 | $6.20M 10-Q · filed 2021-05-07 | $11.63M derived: sum of 2 quarters · filed 2022-03-01 | $17.06M derived: sum of 3 quarters · filed 2022-03-01 | $22.29M derived: sum of 4 quarters · filed 2022-03-01 | |||
| 2019-12-31 | $5.43M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $10.85M derived: sum of 2 quarters · filed 2022-03-01 | $16.08M derived: sum of 3 quarters · filed 2022-03-01 | $21.31M 10-K · filed 2022-03-01 | |||
| 2019-09-30 | $5.42M 10-Q · filed 2020-11-06 | $10.66M derived: sum of 2 quarters · filed 2020-11-06 | $15.88M 10-Q · filed 2020-11-06 | $21.30M derived: sum of 4 quarters · filed 2021-02-26 | |||
| 2019-06-30 | $5.23M 10-Q · filed 2020-08-07 | $10.46M 10-Q · filed 2020-08-07 | $15.87M derived: sum of 3 quarters · filed 2021-02-26 | $21.31M derived: sum of 4 quarters · filed 2021-02-26 | |||
| 2019-03-31 | $5.23M 10-Q · filed 2020-05-08 | $10.64M derived: sum of 2 quarters · filed 2021-02-26 | $16.08M derived: sum of 3 quarters · filed 2021-02-26 | $21.47M derived: sum of 4 quarters · filed 2021-02-26 | |||
| 2018-12-31 | $5.42M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $10.86M derived: sum of 2 quarters · filed 2021-02-26 | $16.24M derived: sum of 3 quarters · filed 2021-02-26 | $21.58M 10-K · filed 2021-02-26 | |||
| 2018-09-30 | $5.44M 10-Q · filed 2019-11-07 | $10.83M derived: sum of 2 quarters · filed 2019-11-07 | $16.17M 10-Q · filed 2019-11-07 | $21.80M derived: sum of 4 quarters · filed 2020-02-28 | |||
| 2018-06-30 | $5.38M 10-Q · filed 2019-08-09 | $10.72M 10-Q · filed 2019-08-09 | $16.36M derived: sum of 3 quarters · filed 2020-02-28 | $21.90M derived: sum of 4 quarters · filed 2020-02-28 | |||
| 2018-03-31 | $5.34M 10-Q · filed 2019-05-09 | $10.97M derived: sum of 2 quarters · filed 2020-02-28 | $16.51M derived: sum of 3 quarters · filed 2020-02-28 | $22.02M derived: sum of 4 quarters · filed 2020-02-28 | |||
| 2017-12-31 | $5.63M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | $11.17M derived: sum of 2 quarters · filed 2020-02-28 | $16.68M derived: sum of 3 quarters · filed 2020-02-28 | $22.09M 10-K · filed 2020-02-28 | |||
| 2017-09-30 | $5.54M 10-Q · filed 2018-11-08 | $11.05M derived: sum of 2 quarters · filed 2018-11-08 | $16.45M 10-Q · filed 2018-11-08 | $22.00M derived: sum of 4 quarters · filed 2019-03-01 | |||
| 2017-06-30 | $5.51M 10-Q · filed 2018-08-09 | $10.91M 10-Q · filed 2018-08-09 | $16.46M derived: sum of 3 quarters · filed 2019-03-01 | $22.08M derived: sum of 4 quarters · filed 2019-03-01 | |||
| 2017-03-31 | $5.40M 10-Q · filed 2018-05-10 | $10.95M derived: sum of 2 quarters · filed 2019-03-01 | $16.57M derived: sum of 3 quarters · filed 2019-03-01 | $22.19M derived: sum of 4 quarters · filed 2019-03-01 | |||
| 2016-12-31 | $5.55M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $11.16M derived: sum of 2 quarters · filed 2019-03-01 | $16.79M derived: sum of 3 quarters · filed 2019-03-01 | $22.47M 10-K · filed 2019-03-01 | |||
| 2016-09-30 | $5.61M 10-Q · filed 2017-11-08 | $11.24M derived: sum of 2 quarters · filed 2017-11-08 | $16.92M 10-Q · filed 2017-11-08 | $22.71M derived: sum of 4 quarters · filed 2018-03-01 | |||
| 2016-06-30 | $5.63M 10-Q · filed 2017-08-09 | $11.30M 10-Q · filed 2017-08-09 | $17.09M derived: sum of 3 quarters · filed 2018-03-01 | $21.30M derived: sum of 4 quarters · filed 2018-03-01 | |||
| 2016-03-31 | $5.68M 10-Q · filed 2017-05-10 | $11.47M derived: sum of 2 quarters · filed 2018-03-01 | $15.67M derived: sum of 3 quarters · filed 2018-03-01 | $19.79M derived: sum of 4 quarters · filed 2018-03-01 | |||
| 2015-12-31 | $5.79M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $9.99M derived: sum of 2 quarters · filed 2018-03-01 | $14.11M derived: sum of 3 quarters · filed 2018-03-01 | $18.28M 10-K · filed 2018-03-01 | |||
| 2015-09-30 | $4.20M 10-Q · filed 2016-11-04 | $8.32M derived: sum of 2 quarters · filed 2016-11-04 | $12.49M 10-Q · filed 2016-11-04 | $16.95M derived: sum of 4 quarters · filed 2017-03-01 | |||
| 2015-06-30 | $4.12M 10-Q · filed 2016-08-04 | $8.29M 10-Q · filed 2016-08-04 | $12.75M derived: sum of 3 quarters · filed 2017-03-01 | $17.14M derived: sum of 4 quarters · filed 2017-03-01 | |||
| 2015-03-31 | $4.17M 10-Q · filed 2016-05-04 | $8.63M derived: sum of 2 quarters · filed 2017-03-01 | $13.02M derived: sum of 3 quarters · filed 2017-03-01 | $17.51M derived: sum of 4 quarters · filed 2017-03-01 | |||
| 2014-12-31 | $4.46M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $8.85M derived: sum of 2 quarters · filed 2017-03-01 | $13.34M derived: sum of 3 quarters · filed 2017-03-01 | $17.87M 10-K · filed 2017-03-01 | |||
| 2014-09-30 | $4.39M 10-Q · filed 2015-11-06 | $8.88M derived: sum of 2 quarters · filed 2015-11-06 | $13.41M 10-Q · filed 2015-11-06 | $17.98M derived: sum of 4 quarters · filed 2016-02-29 | |||
| 2014-06-30 | $4.49M 10-Q · filed 2015-08-06 | $9.02M 10-Q · filed 2015-08-06 | $13.59M derived: sum of 3 quarters · filed 2016-02-29 | $18.17M derived: sum of 4 quarters · filed 2016-02-29 | |||
| 2014-03-31 | $4.53M 10-Q · filed 2015-05-01 | $9.10M derived: sum of 2 quarters · filed 2016-02-29 | $13.69M derived: sum of 3 quarters · filed 2016-02-29 | $18.34M derived: sum of 4 quarters · filed 2016-02-29 | |||
| 2013-12-31 | $4.57M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $9.15M derived: sum of 2 quarters · filed 2016-02-29 | $13.81M derived: sum of 3 quarters · filed 2016-02-29 | $18.45M 10-K · filed 2016-02-29 | |||
| 2013-09-30 | $4.59M 10-Q · filed 2014-11-07 | $9.24M derived: sum of 2 quarters · filed 2014-11-07 | $13.89M 10-Q · filed 2014-11-07 | $18.57M derived: sum of 4 quarters · filed 2015-02-26 | |||
| 2013-06-30 | $4.66M 10-Q · filed 2014-08-01 | $9.30M 10-Q · filed 2014-08-01 | $13.98M derived: sum of 3 quarters · filed 2015-02-26 | $19.68M derived: sum of 4 quarters · filed 2015-02-26 | |||
| 2013-03-31 | $4.64M 10-Q · filed 2014-05-08 | $9.33M derived: sum of 2 quarters · filed 2015-02-26 | $15.02M derived: sum of 3 quarters · filed 2015-02-26 | $17.59M derived: sum of 4 quarters · filed 2015-02-26 | |||
| 2012-12-31 | $4.68M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-26 | $10.38M derived: sum of 2 quarters · filed 2015-02-26 | $12.94M derived: sum of 3 quarters · filed 2015-02-26 | $15.49M 10-K · filed 2015-02-26 | |||
| 2012-09-30 | $5.70M 10-Q · filed 2013-11-07 | $11.18M 10-Q · filed 2012-11-09 | $8.26M derived: sum of 2 quarters · filed 2013-11-07 | $10.81M 10-Q · filed 2013-11-07 | $23.45M 10-Q · filed 2012-11-09 | $8.28M derived: sum of 4 quarters · filed 2013-11-07 | |
| 2012-06-30 | $2.56M 10-Q · filed 2013-08-09 | $7.93M 10-Q · filed 2012-08-09 | $5.11M 10-Q · filed 2013-08-09 | $12.26M 10-Q · filed 2012-08-09 | $2.58M derived: sum of 3 quarters · filed 2013-08-09 | $5.13M derived: sum of 4 quarters · filed 2013-08-09 | |
| 2012-03-31 | $2.55M 10-Q · filed 2013-05-09 | $4.33M 10-Q · filed 2012-05-04 | $23.00K derived: sum of 2 quarters · filed 2013-05-09 | $2.57M derived: sum of 3 quarters · filed 2013-05-09 | $5.14M derived: sum of 4 quarters · filed 2013-05-09 | ||
| 2011-12-31 | -$2.52M 10-K · filed 2012-02-29 | $18.00K derived: sum of 2 quarters · filed 2012-11-09 | $2.59M derived: sum of 3 quarters · filed 2012-11-09 | $10.22M 10-K · filed 2014-02-27 | |||
| 2011-09-30 | $2.54M 10-Q · filed 2012-11-09 | $5.11M derived: sum of 2 quarters · filed 2012-11-09 | $7.70M 10-Q · filed 2012-11-09 | $5.21M derived: sum of 4 quarters · filed 2012-11-09 | |||
| 2011-06-30 | $2.57M 10-Q · filed 2012-08-09 | $5.16M 10-Q · filed 2012-08-09 | $2.67M derived: sum of 3 quarters · filed 2012-08-09 | -$159.00K derived: sum of 4 quarters · filed 2012-08-09 | |||
| 2011-03-31 | $2.58M 10-Q · filed 2012-05-04 | $97.00K derived: sum of 2 quarters · filed 2012-05-04 | -$2.73M derived: sum of 3 quarters · filed 2012-05-04 | -$5.64M derived: sum of 4 quarters · filed 2012-05-04 | |||
| 2010-12-31 | -$2.49M 10-K · filed 2012-02-29 | -$5.31M derived: sum of 2 quarters · filed 2012-02-29 | -$8.22M derived: sum of 3 quarters · filed 2012-02-29 | $11.17M 10-K · filed 2013-03-01 | |||
| 2010-09-30 | -$2.83M 10-K · filed 2012-02-29 | $2.83M 10-Q · filed 2011-11-04 | -$5.74M derived: sum of 2 quarters · filed 2012-02-29 | $8.69M 10-Q · filed 2011-11-04 | |||
| 2010-06-30 | -$2.91M 10-K · filed 2012-02-29 | $2.91M 10-Q · filed 2011-08-05 | $5.86M 10-Q · filed 2011-08-05 | ||||
| 2010-03-31 | -$2.95M 10-K · filed 2012-02-29 | $2.95M 10-Q · filed 2011-04-29 | |||||
| 2009-12-31 | $12.18M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |